Soquelitinib for Eczema
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is evaluating a new treatment called soquelitinib for individuals with moderate to severe eczema (also known as atopic dermatitis). The main goals are to determine the drug's safety and its effectiveness in reducing eczema symptoms. Participants will receive either varying doses of soquelitinib or a placebo (a pill with no active drug). Suitable candidates have previously tried other eczema treatments without success or found them difficult to tolerate. As a Phase 1 trial, this research aims to understand how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.
Will I have to stop taking my current medications?
Yes, you may need to stop certain medications. The trial requires that you have not taken oral prednisone or similar drugs within 2 weeks before starting, and other immunosuppressive medications within 4 weeks before starting.
Is there any evidence suggesting that soquelitinib is likely to be safe for humans?
Research has shown that soquelitinib was safe in earlier studies. Participants generally tolerated soquelitinib well, and no major safety issues emerged. These studies also found a good balance between safety and effectiveness, supporting its further development for atopic dermatitis, a skin condition that causes itchy, inflamed skin.
As this is a Phase 1 trial, the main focus is on safety and tolerability, ensuring the treatment is safe for people. While detailed safety information is still being gathered, early results appear promising.12345Why do researchers think this study treatment might be promising?
Unlike the standard eczema treatments like topical corticosteroids and calcineurin inhibitors, Soquelitinib acts differently by targeting specific immune pathways involved in inflammation. Researchers are excited about Soquelitinib because it offers a novel approach by directly modulating these pathways, potentially leading to reduced symptoms and fewer side effects. This treatment could be a game-changer for patients who struggle with the limitations of current therapies.
What evidence suggests that soquelitinib might be an effective treatment for eczema?
Research has shown that soquelitinib, which participants in this trial may receive, may help treat moderate to severe eczema. In one study, patients who took 200 mg of soquelitinib twice a day experienced faster and more significant symptom improvements compared to those taking different doses. The treatment was also generally safe and well-tolerated. These results suggest that soquelitinib could effectively manage eczema symptoms.23456
Who Is on the Research Team?
Suresh Mahabhashyam, MD
Principal Investigator
Corvus Pharmaceuticals, Inc.
Are You a Good Fit for This Trial?
Adults over 18 with moderate to severe atopic dermatitis (eczema) who haven't had success with certain topical or systemic therapies can join. Participants must use contraception and women of childbearing potential must follow specific contraceptive guidance.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive soquelitinib or placebo tablets orally at specified dose levels for 28 days
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Soquelitinib
Find a Clinic Near You
Who Is Running the Clinical Trial?
Corvus Pharmaceuticals, Inc.
Lead Sponsor